About the Company
We do not have any company description for Monte Rosa Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GLUE News
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
Shares of Monte Rosa Therapeutics (GLUE) have gained 15.9% over the past four weeks to close the last trading session at $6.93, but there could still be a solid upside left in the stock if short-term ...
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
Shares of Monte Rosa Therapeutics (GLUE) have gained 12.4% over the past four weeks to close the last trading session at $6.70, but there could still be a solid upside left in the stock if short-term ...
Next-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancer
Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous ...
Loading the latest forecasts...